September 16, 2014 3:37 PM ET

Healthcare Equipment and Supplies

Company Overview of B·R·A·H·M·S GmbH

Company Overview

B·R·A·H·M·S GmbH explores, develops, and produces new diagnostic test procedures to improve the diagnosis and thereby the treatment of life-threatening illnesses worldwide. It offers thermo scientific biomarkers. The company’s biomarkers focus on research into biomarkers for in vitro diagnosis in medically relevant indications, such as sepsis; markers for intensive care and cardiovascular diseases; lung diseases; prenatal screening/down's syndrome; tumour diseases; and technology transferor and new technologies. Its products are used for tumor diseases, fertility, prenatal screening, and diseases of the thyroid. The company was founded in 1994 and is based in Hennigsdorf, Germany. B·R·A·H·M·...

Neuendorfstrasse 25

Hennigsdorf,  16761

Germany

Founded in 1994

Phone:

49 3302 883 0

Fax:

49 3302 883 100

Key Executives for B·R·A·H·M·S GmbH

Vice President of Business Development
General Manager and Member of Management Board
General Manager and Member of Management Board
General Manager and Member of Management Board
Director of Intellectual Property Development
Compensation as of Fiscal Year 2014.

B·R·A·H·M·S GmbH Key Developments

diaDexus, Inc. Enters into a License and Supply Agreement with B.R.A.H.M.S. Gmbh

On March 4, 2014, diaDexus Inc. entered into a License and supply agreement with B.R.A.H.M.S. GmbH, which is part of Thermo Fisher Scientific Inc. family of companies. Under the agreement, the company obtained an exclusive license from BRAHMS to develop and commercialize high throughput immunoassays for three independent biomarkers (MR-proADM and MR-proANP and CT-proET-1) in the United States for the prognosis or diagnosis of cardiac or cardiovascular disease. The agreement also provides the company with an option to obtain a co-exclusive license in additional countries outside the United States, subject to reasonable payments to be negotiated. The company will be responsible for the development of the licensed immunoassay products, using the biological materials purchased from BRAHMS. Upon completion of the development of the licensed immunoassay products, the company will transfer the commercial production of any such licensed immunoassay products to BRAHMS and company will purchase the licensed immunoassay products from BRAHMS for commercial sale at a specified cost-based transfer price. The agreement includes customary terms, such as forecast, ordering, delivery, inspection for the purchase and supply of licensed immunoassay products. The agreement will expire upon the expiration of the licensed patents covering the licensed immunoassay products, and may be terminated by either party for the other party’s uncured material breach upon written notice. In addition, the company may terminate the agreement upon a minimum specified days advance written notice to BRAHMS, and BRAHMS may terminate the agreement immediately if the company challenges any licensed patents.

Similar Private Companies By Industry

Company Name Region
BYOS Interventional GmbH Europe
Nikkiso Medical Systems GmbH Europe
Cardiomedical GmbH Europe
BERCHTOLD GmbH & Co. KG Europe
IMI Intelligent Medical Implants GmbH Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact B·R·A·H·M·S GmbH, please visit www.brahms.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.